$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000147793222008323 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$18.60K	$55.00K	$10.00K
YoY Change	-72.55%	450.0%	-87.01%
Cost Of Revenue	$5.700K	$16.00K	$4.000K
YoY Change	-85.55%	300.0%	-77.27%
Gross Profit	$12.90K	$39.00K	$6.000K
YoY Change	-54.42%	550.0%	-89.9%
Gross Profit Margin	69.35%	70.91%	60.0%
Selling, General & Admin	$899.6K	$805.5K	$757.2K
YoY Change	-37.0%	6.37%	165.6%
% of Gross Profit	6973.64%	2065.28%	12620.58%
Research & Development	$5.000M	$230.9K	$59.18K
YoY Change	9900.0%	290.23%
% of Gross Profit	38759.69%	592.15%	986.33%
Depreciation & Amortization	$23.02K	$23.02K	$23.02K
YoY Change	0.0%	0.0%	37.27%
% of Gross Profit	178.45%	59.03%	383.67%
Operating Expenses	$5.000M	$1.059M	$839.4K
YoY Change	233.1%	26.21%	178.08%
Operating Profit	-$4.987M	-$1.020M	-$833.4K
YoY Change	238.63%	22.44%	243.73%
Interest Expense	$0.00	$0.00	$1.305M
YoY Change	-100.0%	-100.0%	351.32%
% of Operating Profit
Other Income/Expense, Net	$62.25K	$38.08K	-$1.010M
YoY Change		-103.77%	-258.5%
Pretax Income	-$6.216M	-$982.3K	-$1.844M
YoY Change	60.39%	-46.72%	-566.91%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.216M	-$982.3K	-$1.844M
YoY Change	60.39%	-46.72%	-566.91%
Net Earnings / Revenue	-33417.69%	-1786.07%	-18435.96%
Basic Earnings Per Share		-$0.07	-$0.75
Diluted Earnings Per Share	-$0.44	-$0.07	-$0.75
COMMON SHARES
Basic Shares Outstanding	14.08M shares	14.07M shares	2.452M shares
Diluted Shares Outstanding		14.07M shares	2.452M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.321M	$16.97M	$2.378M
YoY Change	-22.41%	613.61%	6042.93%
Cash & Equivalents	$8.321M	$16.97M	$2.378M
Short-Term Investments
Other Short-Term Assets	$10.42M	$5.021M
YoY Change
Inventory	$10.19K	$15.89K
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$18.75M	$22.01M	$2.578M
YoY Change	74.6%	753.64%	6559.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K	$3.280K	$3.280K
YoY Change	-0.03%	0.0%
Total Long-Term Assets	$438.9K	$461.9K	$554.0K
YoY Change	-17.34%	-16.62%	43.32%
TOTAL ASSETS
Total Short-Term Assets	$18.75M	$22.01M	$2.578M
Total Long-Term Assets	$438.9K	$461.9K	$554.0K
Total Assets	$19.19M	$22.47M	$3.132M
YoY Change	70.27%	617.39%	636.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.268M	$327.8K	$454.5K
YoY Change	328.89%	-27.87%	31.96%
Accrued Expenses	$39.92K	$54.92K	$29.92K
YoY Change	63.71%	83.56%	-80.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$2.743M
YoY Change		-100.0%	201.97%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.322M	$397.0K	$3.495M
YoY Change	216.21%	-88.64%	9.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.322M	$397.0K	$3.495M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.322M	$397.0K	$3.495M
YoY Change	216.22%	-88.64%	9.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$53.81M	-$47.60M	-$38.80M
YoY Change	23.23%	22.66%
Common Stock	$14.08K	$14.08K	$2.458K
YoY Change	122.07%	472.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.86M	$22.07M	-$363.3K
YoY Change
Total Liabilities & Shareholders Equity	$19.19M	$22.47M	$3.132M
YoY Change	70.27%	617.39%	636.5%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$6.216M	-$982.3K	-$1.844M
YoY Change	60.39%	-46.72%	-566.91%
Depreciation, Depletion And Amortization	$23.02K	$23.02K	$23.02K
YoY Change	0.0%	0.0%	37.27%
Cash From Operating Activities	-$3.591M	-$873.3K	-$390.8K
YoY Change	209.24%	123.47%	124.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$5.057M	-$5.021M	-$200.0K
YoY Change		2410.66%
Cash From Investing Activities	-$5.057M	-$5.021M	-$200.0K
YoY Change	-2628.66%	2410.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	10.00	2.810M
YoY Change	-100.0%	-100.0%	1499.39%
NET CHANGE
Cash From Operating Activities	-3.591M	-873.3K	-390.8K
Cash From Investing Activities	-5.057M	-5.021M	-200.0K
Cash From Financing Activities	0.000	10.00	2.810M
Net Change In Cash	-8.649M	-5.895M	2.219M
YoY Change	-203.63%	-365.6%	131221.89%
FREE CASH FLOW
Cash From Operating Activities	-$3.591M	-$873.3K	-$390.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Expense InterestExpense	1875687	usd
	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	0	usd
	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	26030549	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	38083	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-982339	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-982339	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14068412	shares
CY2021Q4	us-gaap	Management Fee Payable ManagementFeePayable	250000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14194	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14194	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5021307	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	443239	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001187953
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	100000	usd
	celz	Expiration Period Of Finite Lived Intangible Assets ExpirationPeriodOfFiniteLivedIntangibleAssets	2025
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53500
	dei	Entity Registrant Name EntityRegistrantName	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0622284
	dei	Entity Address Address Line1 EntityAddressAddressLine1	211 E Osborn Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Phoenix
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85012
	dei	City Area Code CityAreaCode	480
	dei	Local Phone Number LocalPhoneNumber	399-2822
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	CELZ
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2485	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14076246	shares
CY2022Q3	us-gaap	Management Fee Payable ManagementFeePayable	0	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	0	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	1305273	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q3	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	0	usd
CY2021Q3	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	489157	usd
	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	585601	usd
CY2022Q3	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	0	usd
CY2021Q3	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	-194044	usd
	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	0	usd
CY2022Q3	us-gaap	Other Income OtherIncome	38083	usd
CY2021Q3	us-gaap	Other Income OtherIncome	0	usd
	us-gaap	Other Income OtherIncome	38083	usd
	us-gaap	Other Income OtherIncome	0	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1010160	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	38083	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24740463	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1843596	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3928352	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23087241	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1843596	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3928352	usd
	us-gaap	Net Income Loss NetIncomeLoss	23087241	usd
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.98
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.77
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2452076	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9872450	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2313005	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14068412	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2452076	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9872450	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2363145	shares
	us-gaap	Profit Loss ProfitLoss	3928352	usd
	us-gaap	Profit Loss ProfitLoss	-23087241	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69063	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1755104	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	26030549	usd
	celz	Increase In Principal And Accrued Interest Balances Due To Penalty Provision IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision	0	usd
	celz	Increase In Principal And Accrued Interest Balances Due To Penalty Provision IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision	93821	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	585601	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2485	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5028	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-434019	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	103626	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	30535	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	26169	usd
	celz	Increase Decrease In Management Fee Payable IncreaseDecreaseInManagementFeePayable	0	usd
	celz	Increase Decrease In Management Fee Payable IncreaseDecreaseInManagementFeePayable	-168700	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4205732	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1054446	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	5021307	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	0	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	0	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15471775	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	457	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3887750	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	105000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	celz	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	0	usd
	celz	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	3282	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	435040	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	462000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	226500	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	220000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	705405	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15472232	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3534364	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6245193	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2279918	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10723870	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98012	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16969063	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2377930	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	9186	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	celz	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	0	usd
	celz	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	27725	usd
	celz	Warrants Issued With Notes Payable As A Service Fee WarrantsIssuedWithNotesPayableAsAServiceFee	0	usd
	celz	Warrants Issued With Notes Payable As A Service Fee WarrantsIssuedWithNotesPayableAsAServiceFee	2097629	usd
	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	0	usd
	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	13747415	usd
	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	250000	usd
	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	50000	usd
	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	0	usd
	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	134640	usd
	celz	Exchange Of Preferred Stock For Notes Payable ExchangeOfPreferredStockForNotesPayable	0	usd
	celz	Exchange Of Preferred Stock For Notes Payable ExchangeOfPreferredStockForNotesPayable	572275	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	usd
	celz	Issuance Of Common Stock And Accompanying Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount	15471775	usd
	celz	Common Stock Issued For Related Party Patent Liabilities Amount CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount	250000	usd
	celz	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	457	usd
	celz	Stock Based Compensation StockBasedCompensation	59584	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3928352	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22071204	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	153980	usd
CY2021Q3	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	138731	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23044369	usd
CY2022Q3	celz	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	12	usd
CY2022Q3	celz	Stock Based Compensation StockBasedCompensation	9162	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-982339	usd
	celz	Dividends On Preferred Stock DividendsOnPreferredStock	-27725	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22071204	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-39803010	usd
	celz	Proceeds From Sales Of Preferred Stock Amount ProceedsFromSalesOfPreferredStockAmount	462000	usd
	celz	Common Stock Issued For Related Party Management Liabilities Amount CommonStockIssuedForRelatedPartyManagementLiabilitiesAmount	50000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1383331	usd
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	12364084	usd
	celz	Cashless Exercise Of Warrants Amount CashlessExerciseOfWarrantsAmount	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2097629	usd
	celz	Preferred Stock Redemptions Amounts PreferredStockRedemptionsAmounts	-572275	usd
	celz	Stock Based Compensation StockBasedCompensation	595380	usd
	us-gaap	Net Income Loss NetIncomeLoss	23087241	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-363345	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-714453	usd
CY2021Q3	celz	Dividends On Preferred Stock DividendsOnPreferredStock	-6973	usd
CY2021Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2097629	usd
CY2021Q3	celz	Preferred Stock Redemptions Amounts PreferredStockRedemptionsAmounts	-572275	usd
CY2021Q3	celz	Stock Based Compensation StockBasedCompensation	383612	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1843596	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-363345	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates</strong></em> – The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q2	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
	celz	Weighted Average Common Shares Outstanding Used In Calculating Basic Earnings Per Share WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare	2313005	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	50140	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2363145	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	23087241	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	23087241	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q1	celz	Restricted Common Stock RestrictedCommonStock	431111	usd
	celz	Amortization Expenses AmortizationExpenses	7479	usd
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	33507	usd
	celz	Expected Amount Of Amortization ExpectedAmountOfAmortization	9972	usd
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2019Q4	celz	Common Stock Issue Share CommonStockIssueShare	6667	shares
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2021Q1	celz	Common Stock Issue Share CommonStockIssueShare	133	shares
CY2020Q3	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2020Q3	celz	Common Stock Issue Share CommonStockIssueShare	84656	shares
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2021Q1	celz	Common Stock Issue Share CommonStockIssueShare	89286	shares
CY2020Q4	celz	License Fees LicenseFees	250000	usd
CY2020Q4	celz	License Agreement Description LicenseAgreementDescription	the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
CY2020Q4	celz	License Agreement Description Final LicenseAgreementDescriptionFinal	Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty
	celz	Beginning Balance BeginningBalance	760000	usd
	celz	Accumulated Amortization Beginning Balance AccumulatedAmortizationBeginningBalance	-232321	usd
	celz	Accumulated Amortization Addition Of New Assets AccumulatedAmortizationAdditionOfNewAssets	0	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	usd
	celz	Accumulated Amortization AccumulatedAmortization	-69063	usd
	celz	Ending Balance EndingBalance	760000	usd
	celz	Accumulated Amortization Ending Balance AccumulatedAmortizationEndingBalance	-301384	usd
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2021Q2	celz	Proceeds From Director ProceedsFromDirector	150000	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
CY2021Q3	celz	Aggregate Principal Amount2 AggregatePrincipalAmount2	4456176	usd
CY2021Q3	celz	Aggregate Principal Amount For Bridge Notes AggregatePrincipalAmountForBridgeNotes	690000	usd
CY2021Q3	us-gaap	Financing Receivable Revolving FinancingReceivableRevolving	758426	usd
	celz	Stock Issued To Common Stock StockIssuedToCommonStock	363046	shares
CY2020Q3	celz	Company Paid CompanyPaid	40000	usd
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2019Q4	celz	Cash Payment In Intial Payment CashPaymentInIntialPayment	50000	usd
	celz	Initial Exercise Price InitialExercisePrice	14.175
	celz	Placement Agent Fee PlacementAgentFee	312750	usd
	celz	Amortization Of Debt Discounts AmortizationOfDebtDiscounts	1755104	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
	celz	Debt Conversion Shares Issued DebtConversionSharesIssued	789727	shares
	celz	Aggregate Of Outstanding Principal Interest And Fees AggregateOfOutstandingPrincipalInterestAndFees	1383331	usd
	celz	Debt Conversion Converrted Instrument Shares Issued DebtConversionConverrtedInstrumentSharesIssued	37870	shares
	celz	Common Stock Issued For Cashless Warrant Exercise Shares CommonStockIssuedForCashlessWarrantExerciseShares	43167	shares
	celz	Initial Derivative Liabilities InitialDerivativeLiabilities	1077757	usd
	celz	Dividend Yield DividendYield	0	pure
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0010	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y
	celz	Convertible Notes Payables ConvertibleNotesPayables	697602	usd
CY2021Q3	celz	Aggregate Principal Amount1 AggregatePrincipalAmount1	4456176	usd
	celz	Annual Dividend Yield AnnualDividendYield	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0081	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9295	pure
CY2022Q3	us-gaap	Share Price SharePrice	1.69
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2991669	shares
CY2022Q2	celz	Purchase Of Warrants Shares PurchaseOfWarrantsShares	4563887	shares
CY2022Q2	celz	Purchase Of Pre Funded Warrant And Related Common Warrant PurchaseOfPreFundedWarrantAndRelatedCommonWarrant	15111112	shares
CY2022Q2	celz	Combined Offering Price Of Pre Funded Warrant And Related Common Warrant CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant	2.25
CY2022Q2	celz	Description Of Amendment DescriptionOfAmendment	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
	celz	Common Warrants Exercise Price CommonWarrantsExercisePrice	2.00
	celz	Pre Funded Warrants Exercise Price PreFundedWarrantsExercisePrice	0.0001

Files In Submission

Name	View Source	Status
0001477932-22-008323-index-headers.html	Edgar Link	pending
0001477932-22-008323-index.html	Edgar Link	pending
0001477932-22-008323.txt	Edgar Link	pending
0001477932-22-008323-xbrl.zip	Edgar Link	pending
celz-20220930.xsd	Edgar Link	pending
celz_10q.htm	Edgar Link	pending
celz_10qimg1.jpg	Edgar Link	pending
celz_ex311.htm	Edgar Link	pending
celz_ex312.htm	Edgar Link	pending
celz_ex321.htm	Edgar Link	pending
celz_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
celz-20220930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celz-20220930_pre.xml	Edgar Link	unprocessable
celz-20220930_lab.xml	Edgar Link	unprocessable
celz_10q_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
celz-20220930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2022 Q4 Form 10-Q Financial Statement

#000147793222008323 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2022 Q4 Form 10-Q Financial Statement

#000147793222008323 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz